Pfizer Inc (PFE)

Inventory turnover

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cost of revenue (ttm)	US$ in thousands	21,905,000	24,588,000	28,616,000	26,813,000	28,479,000	29,535,000	24,995,000	30,824,000	34,761,000	34,849,000	38,759,000	36,742,000	30,969,000	24,152,000	16,708,000	11,940,000	10,107,000	9,796,000	9,869,000	10,164,000
Inventory	US$ in thousands	10,851,000	11,721,000	11,447,000	10,892,000	10,189,000	10,204,000	10,310,000	9,541,000	8,981,000	9,513,000	10,454,000	9,979,000	9,059,000	8,640,000	8,948,000	8,493,000	8,046,000	9,295,000	8,564,000	8,423,000
Inventory turnover		2.02	2.10	2.50	2.46	2.80	2.89	2.42	3.23	3.87	3.66	3.71	3.68	3.42	2.80	1.87	1.41	1.26	1.05	1.15	1.21

December 31, 2024 calculation

Inventory turnover = Cost of revenue (ttm) ÷ Inventory
= $21,905,000K ÷ $10,851,000K
= 2.02

Pfizer Inc's inventory turnover ratio, which measures how efficiently the company manages its inventory, exhibited fluctuations over the period from March 31, 2020, to December 31, 2024. The inventory turnover ratio started at 1.21 on March 31, 2020, indicating that Pfizer turned over its inventory 1.21 times during that period.

Subsequently, the ratio slightly decreased to 1.15 by June 30, 2020, and further declined to 1.05 by September 30, 2020. However, the trend reversed, showing an improvement in inventory turnover efficiency, with the ratio increasing to 1.26 by December 31, 2020.

From March 31, 2021, to June 30, 2022, Pfizer's inventory turnover ratio continued to rise steadily. Notably, there was a significant increase in inventory turnover efficiency from September 30, 2021 (2.80), to December 31, 2022 (3.87). This indicates that Pfizer was managing its inventory more effectively during these periods.

However, from March 31, 2023, to December 31, 2024, the inventory turnover ratio showed a slight decline, fluctuating between 2.42 and 2.02. This downward trend might suggest potential changes in Pfizer's inventory management practices or demand for its products.

Overall, Pfizer's inventory turnover ratio demonstrated a mix of fluctuations and improvements over the analyzed period, indicating variations in the company's inventory management efficiency. Further analysis of the factors influencing these changes could provide additional insights into Pfizer's operational performance.